Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.

Breast cancer research : BCR - 15 Nov 2023

Verschoor Noortje, Smid Marcel, Jager Agnes, Sleijfer Stefan, Wilting Saskia M, Martens John W M

Abstract excerpt

BACKGROUND: In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact characteristics which prohibit clinical response to anti-HER2 therapies and drive disease progression are not yet fully known. Integrative whole-genome and transcriptomic sequencing data from both primary and metastatic HER2-positive breast cancer will enhance our understanding of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Profiling

Share to Genomics

Share to Mutation

Share to Receptor, ErbB-2

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 37968696
DOI: 10.1186/s13058-023-01743-z
PMCID: PMC10648326

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.PMID 37968696Read ↗

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.Semantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancerSemantic proximity Read ↗

Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Novel insights into breast cancer genetic variance through RNA sequencing.Semantic proximity Read ↗

Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.Semantic proximity Read ↗

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.Semantic proximity Read ↗

Genomic Divergence Between Matched Primary and Metastatic Tumors Across Cancer Types: A Pan-Cancer Analysis of 5,692 SamplesSemantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumorsSemantic proximity Read ↗

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.